During the past decade, Oncology Hematology Care Inc-Blue Ash conducted 48 clinical trials. In the 10-year time frame, 48 clinical trials started and 59 clinical trials were completed, i.e. on average, 122.9% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 47 clinical trials were completed. i.e. 4700% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Oncology Hematology Care Inc-Blue Ash" #1 sponsor was "National Cancer Institute (NCI)" with 40 trials, followed by "SWOG Cancer Research Network" with 20 trials sponsored, "Alliance for Clinical Trials in Oncology" with 12 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 6 trials sponsored and "Gynecologic Oncology Group" with 6 trials sponsored. Other sponsors include 9 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Oncology Hematology Care Inc-Blue Ash" #1 collaborator was "National Cancer Institute (NCI)" with 50 trials as a collaborator, "NRG Oncology" with 7 trials as a collaborator, "Canadian Cancer Trials Group" with 6 trials as a collaborator, "SWOG Cancer Research Network" with 3 trials as a collaborator and "American College of Surgeons" with 2 trials as a collaborator. Other collaborators include 16 different institutions and companies that were collaborators in the rest 23 trials.

According to Clinical.Site data, the most researched conditions in "Oncology Hematology Care Inc-Blue Ash" are "Recurrent Squamous Cell Lung Carcinoma" (9 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (7 trials), "Breast Cancer" (6 trials), "Recurrent Breast Carcinoma" (5 trials) and "Colorectal Cancer" (4 trials). Many other conditions were trialed in "Oncology Hematology Care Inc-Blue Ash" in a lesser frequency.

Most popular intervention types in "Oncology Hematology Care Inc-Blue Ash" are "Drug" (88 trials), "Other" (65 trials), "Biological" (29 trials), "Procedure" (17 trials) and "Radiation" (13 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (46 trials), "Quality-of-Life Assessment" (22 trials), "Carboplatin" (13 trials), "Cisplatin" (11 trials) and "Docetaxel" (10 trials). Other intervention names were less common.

The vast majority of trials in "Oncology Hematology Care Inc-Blue Ash" are 74 trials for "All" genders, 21 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Oncology Hematology Care Inc-Blue Ash". undefined are not yet recruiting, 8 are recruiting, 51 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 31 completed trials in Oncology Hematology Care Inc-Blue Ash, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Oncology Hematology Care Inc-Blue Ash, 4 "Phase 1" clinical trials were conducted, 46 "Phase 2" clinical trials and 55 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".